Pramlintide (acetate hydrate) inhibits the growth of HCT-116 and HT-29 in a dose-dependent manner, with higher efficacy for the latter (IC50 of 48.67 and 9.10 μg/mL, respectively).
Adding 5, 10, and 20 μg/mL Pramlintide (acetate hydrate) in combination with 5-fluorouracil, oxaliplatin, or irinotecan synergistically induces anti proliferative effects in HCT-116 and HT-29.